Briumvi’s Impact Highlighted in Medical Journals
TG Therapeutics announced the publication of two articles, one examining the evolution of CD20 treatments for multiple sclerosis (MS)...
Rhythm’s Obesity Drug Shows -19.8% Placebo-Adjusted BMI Reduction in Phase 3
Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity. The...
IBIO-600 Primate Data Shows Extended Half-Life and Muscle Growth
iBio announced promising preclinical data for IBIO-600, a long-acting anti-myostatin antibody, and a first-in-class Activin E antibody, both targeting...
What Experts Are Saying About RWD in Clinical Trials
At the 2025 SCOPE Summit Conference, industry leaders gathered to discuss the integration of real-world data (RWD) into clinical...
TR1X Awarded $8M Grant for TRX103 GvHD Trial
Tr1X, a clinical-stage biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to...
Son-1010 Shows Strong Safety in Ovarian Cancer Treatment
Sonnet BioTherapeutics announced positive safety results for SON-1010, an IL-12 based immunotherapy, combined with atezolizumab in a Phase 1b/2a...
ARV-102: First-in-Human Data Shows Blood-Brain Barrier Penetration
Arvinas presented positive Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, a protein implicated in...
Anavex Life Sciences Announces Positive 4-Year Blarcamesine Results
Anavex Life Sciences announced positive data from its ATTENTION-AD trial, a long-term extension of a Phase 2b/3 study evaluating...
GlucoTrack & OneTwo Analytics Partner for CGM Clinical Study
Glucotrack, Inc. (Nasdaq: GCTK) is partnering with OneTwo Analytics AB to analyze clinical study data from its Continuous Blood...
Neurona Therapeutics Raises $102M for Epilepsy Cell Therapy Trial
Neurona Therapeutics secured $102 million in an oversubscribed financing round to advance its allogeneic cell therapy candidate, NRTX-1001, for...